Is a lower-dose, subcutaneous contraceptive injectable containing depot medroxyprogesterone acetate likely to impact women's risk of HIV?

Saved in:
Bibliographic Details
Published inContraception (Stoneham) Vol. 97; no. 3; pp. 191 - 197
Main Authors Polis, Chelsea B., Achilles, Sharon L., Hel, Zdenek, Hapgood, Janet P.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.03.2018
Subjects
Adolescent
Adult
Africa South of the Sahara
Contraception - adverse effects
Contraception - methods
Contraceptive Agents, Female - administration & dosage
Delayed-Action Preparations
Female
HIV
HIV Infections - etiology
Humans
Injections, Subcutaneous
Medroxyprogesterone Acetate - administration & dosage
Risk Factors
Young Adult
Africa South of the Sahara
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
All authors contributed equally to the writing of this manuscript.
ISSN:0010-7824
1879-0518
DOI:10.1016/j.contraception.2017.12.003